Prevention of Cisplatin-induced ototoxicity

Phase 3

• Conditions: Condition 1: Hearing loss. Condition 2: Hearing loss. Condition 3: Hearing loss. Condition 4: Hearing loss.; Other and unspecified types of non-Hodgkin lymphoma; Hodgkin lymphoma; Non-follicular lymphoma; Malignant neoplasm of stomach

• Registration Number: IRCT2016081927286N1
• Lead Sponsor: Investigator

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

patients with cancer who are scheduled to receive Cisplatin; aged 20 to 65 years.
Exclusion criteria: previous use of Cisplatin or any ototoxic drug; patients with Head and Neck cancer; age above 65 years; patients who use hearing aids or those associated with hearing loss in the past otalgic disease; Steroid user; patients with systemic diseases such as Diabetes, Hypertension, Thyroid disease, Kidney or Liver disease; pregnant or lactating women; patients with a history of Seizure; taking Monoamine Oxidase inhibitors; concomitant use of Antidepressants drugs; history of radiotherapy.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hearing frequencie. Timepoint: Before the intervention, After the intervention. Method of measurement: Distorsion product Otoacoustic Emission, High frequency tympanoaudiometery.

Secondary Outcome Measures

Name	Time	Method
The side effects of taking Sertraline. Timepoint: Before the intervention, After the intervention. Method of measurement: Interview.